BioMarin Pharmaceutical
American company
BMRN Nasdaq
ISIN US09061G1013 SEC CIK 1048477 LEI NSLL8ITTRR0J5HEMR848
Follow BioMarin Pharmaceutical
Weekly email: filings, results
Revenue, last quarter
$1B
+32% vs same quarter last year
Net income
−$122.8M
−299.5% vs same quarter last year
EPS, diluted
−$0.63
−293.8% vs same quarter last year
Operating cash flow
$188.2M
−48.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $3.2B | $348.9M |
| FY24 | $2.9B | $426.9M |
| FY23 | $2.4B | $167.6M |
| FY22 | $2.1B | $141.6M |
| FY21 | $1.8B | −$64.1M |
| FY20 | $1.9B | $854M |
| FY19 | $1.7B | −$23.8M |
| FY18 | $1.5B | −$77.2M |
| FY17 | $1.3B | −$117M |
| FY16 | $1.1B | −$630.2M |
| FY15 | $889.9M | −$171.8M |
| FY14 | $749.3M | −$134M |
| FY13 | $548.5M | −$176.4M |
| FY12 | $500.7M | −$114.3M |
| FY11 | $441.4M | −$53.8M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 77.7% | 12.7% | 10.8% |
| FY24 | 79.7% | 17% | 15% |
| FY23 | 78% | 7.7% | 6.9% |
| FY22 | 76% | 7.7% | 6.8% |
| FY21 | 74.5% | −4.5% | −3.5% |
| FY20 | 71.8% | −2.3% | 45.9% |
| FY19 | 78.9% | −5.9% | −1.4% |
| FY18 | 78.9% | −8.3% | −5.2% |
| FY17 | 81.6% | −1.1% | −8.9% |
| FY16 | 81.2% | −71.9% | −56.4% |
| FY15 | 82.9% | −12.4% | −19.3% |
| FY14 | 83.7% | −12.4% | −17.9% |
| FY13 | 83.9% | −28.4% | −32.2% |
| FY12 | 81.7% | −22% | −22.8% |
| FY11 | 81% | −7.7% | −12.2% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $725M |
| FY24 | $487.4M |
| FY23 | $62.6M |
| FY22 | $54.9M |
| FY21 | $209M |
| FY20 | −$28.9M |
| FY19 | −$96.8M |
| FY18 | −$124.4M |
| FY17 | −$208M |
| FY16 | −$376.2M |
| FY15 | −$447.2M |
| FY14 | −$187.5M |
| FY13 | −$124.8M |
| FY12 | −$27M |
| FY11 | −$54.8M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | $0 |
| FY21 | $0 |
| FY20 | $50M |
| FY19 | $0 |
| FY18 | $0 |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
- BioMarin Pharmaceutical
- Healthcare median
Show the numbers
| Year | BioMarin Pharmaceutical | Healthcare median |
|---|---|---|
| FY25 | 10.8% | −30.6% |
| FY24 | 15% | −47% |
| FY23 | 6.9% | −58% |
| FY22 | 6.8% | −80.4% |
| FY21 | −3.5% | −71.9% |
| FY20 | 45.9% | −62.2% |
| FY19 | −1.4% | −46.3% |
| FY18 | −5.2% | −49.6% |
| FY17 | −8.9% | −45.9% |
| FY16 | −56.4% | −36% |
| FY15 | −19.3% | −38.4% |
| FY14 | −17.9% | −35.5% |
| FY13 | −32.2% | −37.1% |
| FY12 | −22.8% | −29.1% |
| FY11 | −12.2% | −27.9% |